Article

Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]

MRC Research Unit on Anxiety Disorders, University of Stellenbosch, Cape Town, South Africa.
BMC Psychiatry (Impact Factor: 2.24). 02/2005; 5:5. DOI: 10.1186/1471-244X-5-5
Source: PubMed

ABSTRACT Although serotonin reuptake inhibitors are effective in the treatment of OCD, many patients fail to respond to these agents. Growing evidence from open-label and placebo-controlled trials suggests a role for augmentation of SRIs with atypical antipsychotics in OCD. Quetiapine is generally well tolerated and previous open-label data has produced mixed results in OCD and additional controlled data is needed.
We undertook a double-blind, randomised, parallel-group, flexible-dose, placebo-controlled study of quetiapine augmentation in subjects who had responded inadequately to open-label treatment with an SRI for 12 weeks. Following informed consent and screening, forty-two subjects were randomised to either placebo or quetiapine for six weeks.
There was significant improvement from baseline to endpoint on the Yale-Brown Obsessive-Compulsive Scale in both the quetiapine and placebo groups (quetiapine, n = 20, p < 0.0001; placebo, n = 21, p = 0.001) with 40% (n = 8) of quetiapine and 47.6% (n = 10) of placebo treated subjects being classified as responders. Quetiapine did not demonstrate a significant benefit over placebo at the end of the six-week treatment period (p = .636). Similarly quetiapine failed to separate from placebo in the subgroup of subjects (n = 10) with co-morbid tics. Quetiapine was generally well tolerated.
In this study, quetiapine augmentation was no more effective than placebo augmentation of SRIs. A number of limitations in study design make comparisons with previous studies in this area difficult and probably contributed to our negative findings. Future work in this important clinical area should address these limitations.

Download full-text

Full-text

Available from: Dan J. Stein, Sep 02, 2015
0 Followers
 · 
90 Views
 · 
40 Downloads
  • Source
    • "Symbols: each study is represented by a circle, the area of which is proportional to its statistical weight. Treatment studies: ARI aripiprazole (Muscatello et al. 2011 ; Sayyah et al. 2012), HAL haloperidol (McDougle et al. 1994), OLZ olanzapine (Bystritsky et al. 2004 Shapira et al. 2004), QUE quetiapine (Carey et al. 2005; Denys et al. 2004a, b; Diniz, 2011; Fineberg and Gale 2005; Kordon et al. 2008), RIS risperidone (Erzegovesi et al. 2005; Hollander et al. 2003; McDougle et al. 2000) Psychopharmacology and serotonin receptors were not significantly associated (p>0.05) (Table 3). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The relationship between clinically effective antipsychotic drugs in obsessive-compulsive disorders (OCD) and binding affinities to cloned dopamine and serotonin receptor subtypes was analyzed in an effort to clarify the contribution of individual receptor subtypes to medication response. Meta-analysis was used to update previous meta-analyses of effectiveness data of add-on antipsychotic drugs to selective serotonin reuptake inhibitors (SSRIs) in OCD. Twelve previously analyzed randomized controlled trials (RCTs) and one new RCT were included. We performed a metaregression using a mixed-effect model to examine the association between antipsychotic's effectiveness and receptor affinity. A total of 5 treatment arms obtained from 13 RCTs (431 patients) were included in our study. The results of our metaregression showed a significant association between D2 and D3 dopamine receptor affinities and effectiveness in OCD (respectively, slope = -0.36, p = 0.01; and slope = -0.50, p = 0.01) whereas other dopamine receptors and serotonin receptors were not significantly associated. These observations suggest that increasing D2 and D3 dopamine receptor binding affinities enhances antipsychotics' effectiveness in obsessive-compulsive disorders.
    Psychopharmacology 03/2014; 231(18). DOI:10.1007/s00213-014-3516-3 · 3.99 Impact Factor
  • Source
    • "Open studies and case reports have evaluated the efficacy of quetiapine as addon therapy in obsessional states.86,87 In OCD patients refractory to at least two SSRI trials, quetiapine 200 mg/day was shown to be significantly more efficacious than SSRI monotherapy in reducing obsessive symptoms, with 40% of patients rated as responders. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Obsessional states show an average point prevalence of 1%-3% and a lifetime prevalence of 2%-2.5%. Most treatment-seeking patients with obsessions continue to experience significant symptoms after 2 years of prospective follow-up. A significant burden of impairment, distress, and comorbidity characterize the course of the illness, leading to an increased need for a better understanding of the nature and management of this condition. This review aims to give a representation of the current pharmacological and psychotherapeutic strategies used in the treatment of obsessive-compulsive disorder. Antidepressants (clomipramine and selective serotonin reuptake inhibitors) are generally the first-line choice used to handle obsessional states, showing good response rates and long-term positive outcomes. About 40% of patients fail to respond to selective serotonin reuptake inhibitors. So far, additional pharmacological treatment strategies have been shown to be effective, ie, administration of high doses of selective serotonin reuptake inhibitors, as well as combinations of different drugs, such as dopamine antagonists, are considered efficacious and well tolerated strategies in terms of symptom remission and side effects. Psychotherapy also plays an important role in the management of obsessive-compulsive disorder, being effective for a wide range of symptoms, and many studies have assessed its long-term efficacy, especially when added to appropriate pharmacotherapy. In this paper, we also give a description of the clinical and psychological features likely to characterize patients refractory to treatment for this illness, with the aim of highlighting the need for greater attention to more patient-oriented management of the disease.
    Neuropsychiatric Disease and Treatment 09/2011; 7:599-610. DOI:10.2147/NDT.S17032 · 2.15 Impact Factor
  • Source
    • "While the antipsychotic was well tolerated, 30% of patients had an increase in weight. Carey et al found no difference in patients augmented with placebo or quetiapine, but pointed out that their findings might reflect a shorter trial of an SSRI before quetiapine augmentation and lower dosages of quetiapine compared with other trials.52 The largest quetiapine placebo-controlled trial (n = 66) to date concluded that quetiapine was significantly superior to placebo on Y-BOCS score and CGI scale score, but quetiapine augmentation was associated with more patients discontinuing treatment as a result of adverse events.53 "
    [Show abstract] [Hide abstract]
    ABSTRACT: This article aims to highlight current trends in the pharmacologic management of obsessive-compulsive disorder (OCD). A systematic search of the electronic database MEDLINE was conducted. The first case report of clomipramine efficacy in the management OCD more than 40 years ago gave new hope for the treatment of this debilitating disorder. Selective serotonin reuptake inhibitors (SSRIs) proved to have a similar efficacy profile compared with clomipramine but had a superior tolerability profile. While many patients with OCD respond to SSRIs or clomipramine, the treatment of those with refractory OCD remains challenging. Different augmentation agents in treatment-resistant OCD have been explored, with antipsychotic agents having the largest supporting evidence base. Nevertheless, new pharmacologic treatment options are required and are under investigation.
    Neuropsychiatric Disease and Treatment 05/2010; 6:233-42. DOI:10.2147/NDT.S3149 · 2.15 Impact Factor
Show more